Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OMEPRAZOLE AND SODIUM BICARBONATE vs PRINCIPEN W/ PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.
Duodenal ulcer,Gastric ulcer,Gastroesophageal reflux disease (GERD),Erosive esophagitis,Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Helicobacter pylori eradication (in combination with antibiotics),Prevention of upper gastrointestinal bleeding in critically ill patients (off-label),Treatment of dyspepsia (off-label)
Respiratory tract infections,Urinary tract infections,Meningitis,Septicemia,Endocarditis,Gonorrhea (uncomplicated)
Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.
1.5-3 g IM q6h (20 mg/kg/day probenecid component).
Terminal elimination half-life of omeprazole is approximately 0.5-1 hour. However, the pharmacodynamic effect (gastric acid suppression) lasts longer due to accumulation in parietal cells. Half-life does not correlate with duration of acid suppression.
Ampicillin: 1-1.8 hours (prolonged to 4-6 hours with probenecid due to reduced renal clearance). Probenecid: 6-12 hours. Clinical context: extended half-life allows less frequent dosing.
Omeprazole is extensively metabolized in the liver by cytochrome P450 (CYP) enzymes, primarily CYP2C19 and CYP3A4, to inactive metabolites. Sodium bicarbonate is not metabolized; it dissociates into sodium and bicarbonate ions.
Ampicillin is metabolized by hydrolysis to penicilloic acid; probenecid undergoes hepatic metabolism via glucuronidation and oxidation.
Omeprazole is primarily metabolized by CYP2C19 and CYP3A4; metabolites are excreted renally (~77% as metabolites) and fecally (~20% as metabolites). Urinary excretion of unchanged omeprazole is negligible (<1%). Sodium bicarbonate is excreted renally as bicarbonate and carbon dioxide.
Renal: ~60-80% of ampicillin excreted unchanged in urine via tubular secretion and glomerular filtration; probenecid reduces this to ~20-30%. Biliary/fecal: minor, <10%.
Omeprazole is 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Ampicillin: 15-25% bound to albumin. Probenecid: 85-95% bound to albumin.
Apparent volume of distribution is approximately 0.3-0.5 L/kg, suggesting distribution into total body water. The active form accumulates in parietal cell canaliculi.
Ampicillin: 0.3-0.4 L/kg (distributes well into extracellular fluid, low CNS penetration unless inflamed meninges).
Oral bioavailability is approximately 30-40% after a single dose, increasing to 60-70% with repeated administration due to decreased first-pass metabolism. Bioavailability is not affected by food but is enhanced by the sodium bicarbonate component, which protects omeprazole from acid degradation.
Oral: 30-50% for ampicillin (enhanced by probenecid? probenecid does not significantly alter ampicillin absorption). Probenecid: nearly 100% oral.
No dosage adjustment required for mild to moderate renal impairment; for severe renal impairment (GFR <30 m L/min), use with caution and monitor for sodium overload.
Cr Cl 30-50 m L/min: 1.5 g IM q8h; Cr Cl 10-29 m L/min: 1.5 g IM q12h; Cr Cl <10 m L/min: 1.5 g IM q24h.
For mild hepatic impairment (Child-Pugh class A), no adjustment; for moderate to severe impairment (Child-Pugh class B or C), maximum dose is 20 mg omeprazole once daily due to reduced metabolism.
No adjustment required for mild to moderate impairment. Severe impairment (Child-Pugh C): consider reducing dose by 25-50%.
Not established for omeprazole/sodium bicarbonate combination; for omeprazole alone, weight-based dosing: 10-15 mg once daily for weight 10-20 kg, 20 mg once daily for weight >20 kg.
Children 2-12 years: 50 mg/kg/day IM in 4 divided doses (probenecid component 25 mg/kg/day). Maximum single dose 2 g.
No specific dose adjustment; use lowest effective dose, monitor for electrolyte imbalance (sodium) and increased risk of Clostridium difficile infection.
Reduce dose based on renal function; avoid if Cr Cl <30 m L/min due to probenecid accumulation. Monitor for CNS toxicity.
No FDA black box warning.
None.
Gastric malignancy: Short-term treatment does not preclude presence of gastric malignancy.,Clostridioides difficile infection: May increase risk.,Bone fracture: Long-term use may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.,Hypomagnesemia: May cause low serum magnesium with prolonged use.,Cyanocobalamin (Vitamin B12) deficiency: Prolonged acid suppression may impair absorption.,Acute interstitial nephritis: Has been observed.,Cutaneous lupus erythematosus: May increase risk.,Interaction with methotrexate: May increase methotrexate toxicity.,Sodium content: Contains sodium bicarbonate; caution in patients on sodium-restricted diet.,Metabolic alkalosis: High doses of bicarbonate may cause metabolic alkalosis.
Hypersensitivity reactions including anaphylaxis,Severe cutaneous adverse reactions (SCARs),C. difficile-associated diarrhea,Renal impairment (dose adjustment for ampicillin),Sodium overload with high doses,Allergic cross-reactivity with cephalosporins
Hypersensitivity to omeprazole or sodium bicarbonate,Hypersensitivity to other proton pump inhibitors,Concurrent use of rilpivirine,Severe hypokalemia or metabolic alkalosis (due to bicarbonate component)
Hypersensitivity to penicillins or probenecid,History of cholestyramine or uricosuric agent hypersensitivity,Severe renal impairment (Cr Cl < 30 m L/min) for probenecid-containing products,Blood dyscrasias or uric acid calculi (probenecid)
Avoid taking with food or within 30 minutes of eating. High-fat meals may delay absorption. No specific food restrictions, but alcohol and spicy foods may exacerbate symptoms.
Take with food or milk to reduce gastrointestinal upset. Avoid high-fat meals as they may delay absorption of ampicillin. Probenecid is not affected by food; however, maintain adequate hydration to prevent crystalluria.
First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omeprazole is FDA Pregnancy Category C; sodium bicarbonate is not associated with teratogenicity.
FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratogenic effects. Second/third trimester: Use caution due to potential for altered fetal gut flora. Peripartum: Risk of kernicterus in neonates if maternal hyperbilirubinemia.
Omeprazole is excreted into breast milk with an M/P ratio of approximately 0.1-0.2. Sodium bicarbonate is also excreted. At therapeutic doses, amounts are unlikely to affect the infant. Manufacturer advises caution, but use is generally considered compatible with breastfeeding.
Ampicillin excreted in breast milk in low levels (M/P ratio 0.02-0.1); probenecid probably excreted but data limited. Compatible with breastfeeding; monitor infant for diarrhea, rash, or candidiasis. Theoretical risk of kernicterus in jaundiced infants if probenecid displaces bilirubin.
Pregnancy does not significantly alter omeprazole pharmacokinetics. No dose adjustment required, but use lowest effective dose due to limited safety data. Sodium bicarbonate dose may need adjustment if renal impairment or preeclampsia is present.
Increased renal clearance in pregnancy may reduce ampicillin levels; consider higher doses or more frequent intervals for severe infections. Probenecid dose adjustment not typically required, but monitor for efficacy. Use standard doses for UTI unless resistant organisms suspected.
Administer on an empty stomach 1 hour before a meal for maximal acid suppression. The sodium bicarbonate component provides rapid antacid effect and may cause belching or gastric distension. Avoid in patients with Bartter's syndrome, hypokalemia, or metabolic alkalosis. Monitor magnesium levels with prolonged use; hypomagnesemia can occur with PPIs. For patients unable to swallow capsules, the contents can be mixed with applesauce.
Principen w/ Probenecid combines ampicillin, a broad-spectrum penicillin, with probenecid to prolong ampicillin serum levels by inhibiting renal tubular secretion. Use in penicillin-allergic patients is contraindicated. Probenecid may reduce excretion of other drugs (e.g., methotrexate, NSAIDs). Monitor renal function; probenecid is contraindicated in patients with uric acid kidney stones or blood dyscrasias. Administer with food if GI upset occurs. Synergistic with aminoglycosides but physically incompatible; do not mix in IV solutions.
Take this medication 1 hour before a meal, usually once daily.,Swallow the capsule whole; do not crush or chew. If you have trouble swallowing, open the capsule and mix the granules with a tablespoon of applesauce, then swallow immediately.,Do not take with other antacids unless directed by your doctor.,Inform your doctor if you experience severe diarrhea, muscle cramps, irregular heartbeat, or signs of low magnesium (seizures, dizziness, abnormal heart rhythm).,Long-term use may increase risk of bone fractures, vitamin B12 deficiency, and kidney problems.
Take this medication exactly as prescribed, even if you feel well.,Complete the full course to prevent antibiotic resistance.,May cause diarrhea; contact your doctor if it is severe or contains blood.,Avoid alcohol while taking this medication.,Inform your doctor if you have kidney disease, gout, or a history of penicillin allergy.,Probenecid may increase effects of warfarin; monitor for bleeding.,Drink plenty of fluids to prevent kidney stones while on probenecid.
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OMEPRAZOLE AND SODIUM BICARBONATE vs PRINCIPEN W/ PROBENECID, answered by our medical review team.
OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.. PRINCIPEN W/ PROBENECID is a Uricosuric that works by Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OMEPRAZOLE AND SODIUM BICARBONATE and PRINCIPEN W/ PROBENECID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OMEPRAZOLE AND SODIUM BICARBONATE is: Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.. The standard adult dose of PRINCIPEN W/ PROBENECID is: 1.5-3 g IM q6h (20 mg/kg/day probenecid component).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OMEPRAZOLE AND SODIUM BICARBONATE and PRINCIPEN W/ PROBENECID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omepra. PRINCIPEN W/ PROBENECID is classified as Category A/B. FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratoge. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.